A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Key Inclusion Criteria:

• Males or non-pregnant females aged between 18 and 75 years (inclusive) at time ofsigning the informed consent form (ICF).

• Participants must have type 2 diabetes mellitus diagnosed at least 3 months beforescreening or at least 2 metabolic risk factors.

• Biopsy-confirmed fibrosis stage F4 MASH (NASH Clinical Research Network (CRN)system) with compensated cirrhosis.

• Body mass index (BMI) at screening ≥25.0 (≥23.0 for Asian participants) and <50.0kilograms (kg)/meters squared (m^2).

Key Exclusion Criteria:

• Liver disorder other than MASH.

• History or evidence of hepatic decompensation.

• History or evidence of hepatocellular carcinoma.

• Have type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus.

• ALT or aspartate aminotransferase (AST) ≥250 units per liter (U/L).

• Participants taking vitamin E (>400 international units [IU]/day) must be on stabledose for at least 6 months prior to screening.

Other protocol-defined inclusion and exclusion criteria may apply.